Advisors Preferred’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-161
Closed -$19.6K 296
2025
Q4
$19.6K Buy
+161
New +$18.5K ﹤0.01% 210
2019
Q2
Sell
-178
Closed -$16K 297
2019
Q1
$16K Buy
+178
New +$15.1K 0.01% 177
2015
Q3
Sell
-26,676
Closed -$2.24M 292
2015
Q2
$2.24M Sell
26,676
-3,393
-11% -$264K 1.26% 24
2015
Q1
$2.26M Buy
+30,069
New +$2.1M 1.2% 25
2014
Q2
Sell
-17,592
Closed -$836K 462
2014
Q1
$836K Buy
17,592
+2,343
+15% +$120K 0.38% 76
2013
Q4
$661K Buy
+15,249
New +$631K 0.37% 66

Other funds holding XBI

Advisors Preferred's XBI Position: Q1 2026 in Review

Advisors Preferred sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 161 shares — an estimated $19.6K sold.

Advisors Preferred first reported a position in XBI in Q4 2013 and held it in 6 quarters. The position peaked at $2.26M in Q1 2015. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Advisors Preferred reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Advisors Preferred sold 161 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $19.6K.
  • Advisors Preferred first reported a position in State Street SPDR S&P Biotech ETF in Q4 2013 and held it in 6 quarters.
  • Advisors Preferred's State Street SPDR S&P Biotech ETF position peaked at $2.26M in Q1 2015.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Advisors Preferred's 13F filing for Q1 2026, filed 5 May 2026.